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Fig 2. A, Facial erythromelalgia before therapy. There is prominent full facial erythema and
edema, which may mimic the facial erythema seen in connective tissue diseases. B, Facial
erythromelalgia after treatment. Improvement in erythema and edema 5 months following
initiation of therapy with aspirin, pentoxifylline, gabapentin, and, subsequently, nifedipine.
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manifestation of cutaneous macroglobulinosis
To the Editor: In December 2013, a 70-year-old
man came to our service for nodules covered by a
thick hyperkeratotic layer on the soles of his feet.
The lesions were extremely painful to pressure, to
the extent of limiting his daily activities (Fig 1). They
had appeared about 2 years earlier and were treated
as viral warts with keratolytic agents, without
success.
The patient’s history showed that he had been
followed by the hematology service for 15 years with
periodic clinical evaluations and no therapy for a
diagnosis of Waldenstr€om macroglobulinemia
(WM). The most recent laboratory studies were
unremarkable with no detectable anti-myelin-
associated glycoprotein (anti-MAG) or cryoglobulin.
Serum immunofixation studies revealed the
presence of an IgM-kappa monoclonal protein of
22.9 g/L (0.4-2.5 g/L); urine analysis identified
Bence-Jones (IgM-kappa type) proteinuria. The
patient was otherwise in good health.
On the basis of clinical and laboratory findings,
hematologists recommended no therapy.
A biopsy of 1 of the plantar nodules showed
hyperplastic and hyperkeratotic epidermis, and
moderate perivascular lymphohistiocytic inflamma-
tion with rare plasma cells. In the dermis and in
the intravascular space there was deposition of
an amorphous, homogeneous, intensely periodic
acid-Schiffpositive and Congo rednegative
material. The biopsy specimen was IgM positive
when immunohistochemical stains were used
(Fig 2). Based on the clinical course, histology, and
anamnestic data, we considered a diagnosis of
Fig 2. Cutaneous macroglobulinosis. Material proved
IgM-positive using immunohistochemical stains.
Fig 1. Cutaneous macroglobulinosis. Painful nodules
covered by a thick hyperkeratotic layer on the soles of feet.
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of WM.
WM is a lymphoplasmacytic lymphoma with a
monoclonal IgM paraprotein; it represents about 2%
of all hematologic malignancies and its incidence is
3.8 per million persons per year.1 WM cases usually
have an indolent disease course for many years
preceding clinical presentation related to tumor
infiltration and deposition of monoclonal IgM
paraprotein in tissues.2 The symptoms of neoplastic
infiltration may be due to the replacement of bone
marrow, splenomegaly, and/or lymphadenopathy.
Paraprotein can also lead to hyperviscosity
syndrome, peripheral neuropathy, and immune
complex vasculitis.1
Cutaneousmanifestations ofWMare distinguished
as specific and nonspecific.3 Specific manifestations,
sporadically reported, are related to lymphoplasma-
cytic cell infiltrates or deposits of monoclonal
component in the cutis. Nonspecific manifestations
are the consequence of hyperviscosity or cryoglobu-
linemia such as purpura, livedo reticularis, mucosal
bleeding, and Raynaud phenomenon.4
The accumulation of monoclonal IgM in the
basement membrane zone (BMZ) may present with
pruritic papules or bullous dermatosis when IgM
antibodies are directed to antigens of BMZ.5
The isolated storage of IgM components in
the dermis is known as CM; it is a very rare condition
and clinically presents translucent erythematous
papules that are located on the limbs, buttocks,
and back.4
In our case, the skin lesions were exclusively
localized on the soles and were characterized by
intense pain on pressure.
It seems appropriate to stress the importance
of seeking these localized plantar lesions in CMassociated with pain, which require a specific
treatment for WM.
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